Zhejiang Shengda Pharm - Asset Resilience Ratio

Latest as of March 2026: 1.46%

Zhejiang Shengda Pharm (603079) has an Asset Resilience Ratio of 1.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhejiang Shengda Pharm current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥32.02 Million
≈ $4.69 Million USD Cash + Short-term Investments

Total Assets

CN¥2.19 Billion
≈ $320.83 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Zhejiang Shengda Pharm's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603079 total assets.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Shengda Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Zhejiang Shengda Pharm debt and liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥32.02 Million 1.46%
Total Liquid Assets CN¥32.02 Million 1.46%

Asset Resilience Insights

  • Limited Liquidity: Zhejiang Shengda Pharm maintains only 1.46% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Zhejiang Shengda Pharm Industry Peers by Asset Resilience Ratio

Compare Zhejiang Shengda Pharm's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 9.04%
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
Drug Manufacturers - Specialty & Generic 12.99%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Sun Pharma Advanced Research Company Limited
NSE:SPARC
Drug Manufacturers - Specialty & Generic 0.64%
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
Drug Manufacturers - Specialty & Generic 32.14%

Annual Asset Resilience Ratio for Zhejiang Shengda Pharm (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Shengda Pharm.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 8.28% CN¥182.06 Million
≈ $26.64 Million
CN¥2.20 Billion
≈ $321.72 Million
+8.28pp
2024-12-31 0.00% CN¥14.73K
≈ $2.16K
CN¥1.79 Billion
≈ $261.25 Million
-0.17pp
2023-12-31 0.18% CN¥3.01 Million
≈ $440.97K
CN¥1.72 Billion
≈ $251.57 Million
+0.17pp
2021-12-31 0.00% CN¥14.41K
≈ $2.11K
CN¥1.76 Billion
≈ $258.25 Million
-1.20pp
2018-12-31 1.20% CN¥15.02 Million
≈ $2.20 Million
CN¥1.25 Billion
≈ $183.31 Million
-7.93pp
2017-12-31 9.13% CN¥90.00 Million
≈ $13.17 Million
CN¥985.98 Million
≈ $144.28 Million
--
pp = percentage points

About Zhejiang Shengda Pharm

SHG:603079 China Drug Manufacturers - Specialty & Generic
Market Cap
$362.64 Million
CN¥2.48 Billion CNY
Market Cap Rank
#14037 Global
#4230 in China
Share Price
CN¥13.11
Change (1 day)
-1.28%
52-Week Range
CN¥10.04 - CN¥21.99
All Time High
CN¥53.01
About

Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.